PROspective Trial on EOsinophilia in Non-Small Cell Lung Cancer (NSCLC).

After premedication with 400 μg inhaled salbutamol, sputum will be induced by inhalation of hypertonic (NaCl 3%) or isotonic (NaCl 0.9%) saline combined according to the FEV-1 value (\> or ≤ than 65% predicted). Saline will be combined with additional salbutamol delivered by an ultrasonic nebulizer (Ultra-Neb 2000; Devilbiss, Somerset, PA, USA) with an output set at 0.9 ml/min. Each subject will inhale the aerosol for three consecutive periods of 5 min for a total of 15 min. For safety reasons, FEV-1 will be monitored throughout the induction and will be stopped if FEV-1 would fall by more than 20% from baseline.

As per standard practice, biopsies will be taken from the primary tumour site or from a metastatic site.

When available, the remaining material from a patient's bronchoalveolar lavage will be collected.

As per standard practice, blood will be drawn from patients before and during treatment. Data on white blood cells will be collected.